[锰-二吡哆醛二磷酸酯在肝脏恶性肿瘤磁共振断层成像中的应用。一种新型肝胆造影剂的初步结果]

[Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].

作者信息

Steudel A, Layer G, Kraheck H, Hartlapp J, Reiser M

机构信息

Radiologische Klinik, Rheinische Friedrich-Wilhelms-Universität Bonn.

出版信息

Rofo. 1992 May;156(5):460-4. doi: 10.1055/s-2008-1032921.

DOI:10.1055/s-2008-1032921

PMID:1596550

Abstract

The new hepatobiliary contrast agent Mangan-DPDP, unlike extracellular Gd-DTPA, leads to a constant increase in signal intensity of normal liver tissue in MR imaging of the liver which lasts at least for 30 minutes. In 19 patients with malignant liver tumors there was no difference in the contrast between tumor and liver when using a dose of 5 or 10 mumol/kg. Contrast enhanced T1-w SE- and T1-w GE sequences show a significant increase in tumor/liver contrast compared with T1-weighted unenhanced sequences. This increase was also significant when compared with T2-w SE sequences. In 16% additional focal lesions were detected on the enhanced scan.

摘要

新型肝胆造影剂锰-二吡哆醛二巯基丁二酸（Mangan-DPDP）与细胞外钆-二乙三胺五醋酸（Gd-DTPA）不同，在肝脏的磁共振成像（MR成像）中，它会使正常肝组织的信号强度持续增加，至少持续30分钟。在19例肝恶性肿瘤患者中，使用5或10微摩尔/千克的剂量时，肿瘤与肝脏之间的对比度没有差异。与未增强的T1加权序列相比，对比增强的T1加权自旋回波（SE）序列和T1加权梯度回波（GE）序列显示肿瘤/肝脏对比度显著增加。与T2加权SE序列相比，这种增加也很显著。在增强扫描中还发现了16%的额外局灶性病变。